Target type: biologicalprocess
The process in which a relatively unspecialized T cell acquires the specialized features of a T-helper 1 (Th1) cell. A Th1 cell is a CD4-positive, alpha-beta T cell that has the phenotype T-bet-positive and produces interferon-gamma. [CL:0000545, GOC:ebc]
T-helper 1 (Th1) cell differentiation is a complex process driven by a cascade of signaling events that ultimately lead to the development of effector Th1 cells specialized for mediating cell-mediated immunity. This process begins when naive CD4+ T cells encounter antigen presented by antigen-presenting cells (APCs), such as dendritic cells, in the context of specific MHC II molecules.
The engagement of the T cell receptor (TCR) with its cognate antigen, along with co-stimulatory signals like CD28 engagement by CD80/CD86 on the APC, initiate a cascade of intracellular signaling pathways. These pathways culminate in the activation of transcription factors, including NF-κB, NFAT, and AP-1, which regulate the expression of genes critical for Th1 differentiation.
One key cytokine involved in Th1 differentiation is interleukin-12 (IL-12) produced by APCs. IL-12 binds to its receptor on the T cell, activating the STAT4 signaling pathway, leading to the expression of the transcription factor T-bet. T-bet is a master regulator of Th1 differentiation, inducing the expression of Th1-specific genes, such as IFN-γ, and repressing the expression of genes associated with other T helper lineages, like Th2 and Th17.
IFN-γ, the signature cytokine of Th1 cells, further reinforces the Th1 differentiation program by acting in an autocrine manner. It promotes T-bet expression and inhibits the development of other T helper subsets.
Additionally, Th1 differentiation is influenced by the presence of other cytokines, such as IL-27, which promotes T-bet expression, and IL-2, which supports Th1 cell survival and proliferation.
Furthermore, the expression of the co-inhibitory receptor CTLA-4, induced during Th1 differentiation, acts as a negative feedback mechanism to control the magnitude and duration of the Th1 response.
Th1 differentiation is a tightly regulated process with multiple checkpoints and feedback loops ensuring appropriate activation and suppression of the Th1 response. These complex interactions between signaling pathways, transcription factors, and cytokines ensure the efficient development of Th1 cells and their ability to mount a robust cell-mediated immune response against intracellular pathogens and tumors.'
"
Protein | Definition | Taxonomy |
---|---|---|
High mobility group protein B1 | A high mobility group protein B1 that is encoded in the genome of human. [PRO:DNx, UniProtKB:P09429] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
salicylic acid | Scalp: The outer covering of the calvaria. It is composed of several layers: SKIN; subcutaneous connective tissue; the occipitofrontal muscle which includes the tendinous galea aponeurotica; loose connective tissue; and the pericranium (the PERIOSTEUM of the SKULL). | monohydroxybenzoic acid | algal metabolite; antifungal agent; antiinfective agent; EC 1.11.1.11 (L-ascorbate peroxidase) inhibitor; keratolytic drug; plant hormone; plant metabolite |
diflunisal | diflunisal : An organofluorine compound comprising salicylic acid having a 2,4-difluorophenyl group at the 5-position. Diflunisal: A salicylate derivative and anti-inflammatory analgesic with actions and side effects similar to those of ASPIRIN. | monohydroxybenzoic acid; organofluorine compound | non-narcotic analgesic; non-steroidal anti-inflammatory drug |
glycyrrhizic acid | glycyrrhizinic acid : A triterpenoid saponin that is the glucosiduronide derivative of 3beta-hydroxy-11-oxoolean-12-en-30-oic acid. | enone; glucosiduronic acid; pentacyclic triterpenoid; tricarboxylic acid; triterpenoid saponin | EC 3.4.21.5 (thrombin) inhibitor; plant metabolite |
methotrexate | dicarboxylic acid; monocarboxylic acid amide; pteridines | abortifacient; antimetabolite; antineoplastic agent; antirheumatic drug; dermatologic drug; DNA synthesis inhibitor; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; immunosuppressive agent |